RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Armata Pharmaceuticals - Stock

Armata Pharmaceuticals Stocks 2024

Armata Pharmaceuticals Stocks

36.08 M

Ticker

ARMP

ISIN

US04216R1023

WKN

A2PKLC

In 2024, Armata Pharmaceuticals had 36.08 M outstanding stocks, a 0% change from the 36.08 M stocks in the previous year.

The Armata Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e36.08
2027e36.08
2026e36.08
2025e36.08
2024e36.08
202336.08
202234.29
202124.1
202016.42
20197.83
20181.36
20170.46
20160.07
20150.04
20140.05
20130.01
20120.01
20110.01
2008-
2007-
2006-
2005-
2004-
2003-
2002-

Armata Pharmaceuticals shares outstanding

The number of shares was Armata Pharmaceuticals in 2023 — This indicates how many shares 36.076 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Armata Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Armata Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Armata Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Armata Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Armata Pharmaceuticals Aktienanalyse

What does Armata Pharmaceuticals do?

Armata Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of therapies for severe bacterial infections. The company was founded in California in 2009 and has been listed on the NASDAQ stock exchange since 2019. The founders of Armata Pharmaceuticals Inc. recognized that antibiotic resistance is a growing problem and that it is crucial to develop new therapies to address the challenges in the fight against bacterial infections. The company's business model is based on the discovery and development of bacteriophage therapies. Bacteriophages are natural viruses that can infect and destroy bacteria. Armata Pharmaceuticals Inc. has two main divisions: Armatavax, which focuses on the development of vaccines against bacterial infections, and Armatamab, which works on the development of monoclonal antibodies that express bacteriophage genes and thus have higher efficacy in combating bacteria. The company is currently developing several products based on bacteriophage therapies. The main product is AR-301, a monoclonal antibody designed to treat Staphylococcus infections causing pneumonia. AR-301 is in phase IIb study and has shown promising results. The company also has several other products in the pipeline, including AR-105 against Pseudomonas aeruginosa infections, AR-201 against Acinetobacter baumannii infections, and AR-401 against Enterobacteriaceae infections. Armata Pharmaceuticals Inc. works closely with various academic institutions and research facilities to explore the potential of bacteriophage therapies and develop new products. The company has acquired a number of patents and intellectual property in this area. To bring its products to market, Armata Pharmaceuticals Inc. has formed strategic partnerships with various companies, including AmpliPhi Biosciences, the United States Department of Defense's Drug Agency (DTRA), and Synthetic Biologics. These partnerships enable the company to lower its development costs while increasing access to a broader market. In summary, Armata Pharmaceuticals Inc. is an innovative biopharmaceutical company specializing in the development of bacteriophage therapies for severe bacterial infections. The company has a strong pipeline of products in various stages of development and is actively working to improve its technology and strengthen its market position. Through its partnerships and commitment to cutting-edge research, Armata Pharmaceuticals Inc. ensures that it is well-positioned to address the challenges in the fight against antibiotic resistance. Armata Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Armata Pharmaceuticals's Shares Outstanding

Armata Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Armata Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Armata Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Armata Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Armata Pharmaceuticals Stock

How many stocks are there of Armata Pharmaceuticals?

The current number of stocks of Armata Pharmaceuticals is 36.08 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Armata Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Armata Pharmaceuticals evolved in recent years?

The number of shares of Armata Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Armata Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Armata Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Armata Pharmaceuticals pay?

Over the past 12 months, Armata Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Armata Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Armata Pharmaceuticals?

The current dividend yield of Armata Pharmaceuticals is .

When does Armata Pharmaceuticals pay dividends?

Armata Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Armata Pharmaceuticals?

Armata Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Armata Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Armata Pharmaceuticals located?

Armata Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Armata Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Armata Pharmaceuticals from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did Armata Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/18/2024.

What was the dividend of Armata Pharmaceuticals in the year 2023?

In the year 2023, Armata Pharmaceuticals distributed 0 USD as dividends.

In which currency does Armata Pharmaceuticals pay out the dividend?

The dividends of Armata Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Armata Pharmaceuticals

Our stock analysis for Armata Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Armata Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.